Odronextamab til recidiverende og refraktære storcellede B-celle lymfomer før CAR-T
Odronextamab til recidiverende/refraktære storcellede B-celle lymfomer før endelige lymfom-rettede terapier
This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of improvement (relapsed) or that have not responded to previous treatment (refractory). Odronextamab is a bispecific antibody that can bind to two different antigens at the same time. Odronextamab binds to CD3, a T-cell surface antigen, and CD20 (a tumor-associated antigen that is expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell cancers) and may interfere with the ability of cancer cells to grow and spread. Bridging therapy has been used to maintain disease control and to increase the chance of successful receipt of CAR-T cell therapy. However, bridging therapy is typically given after leukapheresis, which does not help prevent disease progression between the decision for CAR-T cell therapy and leukapheresis. Giving odronextamab as bridging therapy before leukapheresis may delay disease progression to allow leukapheresis and increase the likelihood of successful CAR-T cell therapy in patients with relapsed or refractory large B-cell lymphomas.
Studieoversigt
Status
Status
Betingelser
Betingelser
- Tilbagevendende diffust stort B-cellet lymfom
- Refraktært diffust stort B-cellet lymfom
- Tilbagevendende diffust stort B-cellet lymfom, ikke andet specificeret
- Refraktært diffust stort B-cellet lymfom, ikke andet specificeret
- Tilbagevendende højgradig B-celle lymfom
- Refraktært højgradigt B-celle lymfom
- Tilbagevendende grad 3b follikulært lymfom
- Refraktær grad 3b follikulært lymfom
- Tilbagevendende transformeret indolent B-cellet non-Hodgkin-lymfom til diffust stort B-cellet lymfom
- Refraktært transformeret indolent B-cellet non-Hodgkin-lymfom til diffust stort B-cellet lymfom
- Tilbagevendende primært mediastinalt stort B-celle lymfom
- Refraktært primært mediastinalt stort B-cellet lymfom
Intervention / Behandling
Intervention / Behandling
- Procedure: Bone Marrow Biopsy
- Andet: Questionnaire Administration
- Procedure: Bone Marrow Aspiration
- Procedure: Lumbar Puncture
- Procedure: Positron Emission Tomography
- Procedure: Computed Tomography
- Procedure: Biopsy Procedure
- Procedure: Leukapheresis
- Biologisk: Odronextamab
- Procedure: Biospecimen Collection
- Biologisk: Chimeric Antigen Receptor T-Cell Therapy
Detaljeret beskrivelse
OUTLINE:
Patients receive odronextamab intravenously (IV) on days 1, 2, 8, 9, 15 and 16 of cycle 1 (dose step-up), and on days 1, 8 and 15 of cycles 2-4 and then once every other week of remaining cycles. Cycles repeat every 21 days for the first 4 cycles, then every other week for up to a total of 12 months (including the first 2 cycles). After 2 cycles, patients undergo leukapheresis followed by lymphodepletion and CAR-T infusion per standard of care. If there is a significant delay of leukapheresis, patients may receive up to 12 additional weeks of treatment. Patients who achieve CR after cycle 2 may opt out of leukapheresis and CAR-T cell infusion and may continue to receive odronextamab in the absence of disease progression or unacceptable toxicity. Patients undergo positron emission tomography (PET)/computed tomography (CT), collection of blood and oral or rectal swab samples and tissue biopsy throughout the study. Additionally, patients may undergo lumbar puncture and bone marrow aspiration and/or biopsy on study.
After completion of study treatment, patients are followed till 90 days or the initiation of the next lymphoma directed therapy for toxicity check, and total duration of follow-up is up to 5 years.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Mengyang Di, MD, PhD
- Telefonnummer: 206-606-2519
- E-mail: mydi@fredhutch.org
Studiesteder
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98109
- Rekruttering
- Fred Hutch/University of Washington Cancer Consortium
-
Ledende efterforsker:
- Mengyang Di, MD, PhD
-
Kontakt:
- Mengyang Di, MD, PhD
- Telefonnummer: 206-606-2519
- E-mail: mydi@fredhutch.org
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically confirmed large B cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, DLBCL arising from indolent lymphoma, follicular lymphoma (FL) grade 3B
- Measurable disease, defined as at least one measurable lesion ≥ 15 mm on PET, CT, or magnetic resonance imaging (MRI) within one month of screening, according to the International Working Group consensus response evaluation criteria in lymphoma
- Prior frontline therapy for large B cell lymphoma must have failed the patient, and criteria must be met for receiving commercial axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), or tisagenlecleucel (tisa-cel) per Food and Drug Administration (FDA) label
- Age ≥ 18 years
- Capable of understanding and providing a written informed consent
- Prior treatment with an anti-CD20 antibody therapy
- Eastern Cooperative Oncology Group performance status of 0-1; we allow enrollment of patients with a performance status of 2 if it is attributed to lymphoma per discretion of the treating physician or principal investigator (PI)
- Creatinine clearance ≥ 45 mL/min calculated by Cockcroft-Gault equation
- Total bilirubin ≤ 1.5 x the upper limit of normal (ULN), except in patients with Gilbert's syndrome
- Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x the ULN
- Adequate pulmonary function, defined as ≤ grade 1 dyspnea and oxygen saturation (SpO2) ≥ 92% on room air
- Adequate cardiac function, defined as left ventricular ejection fraction ≥ 50% and without evidence for pericardial effusion
- Platelet count ≥ 75 x 10^9 /L
- Hemoglobin (Hg) level ≥ 9 g/dL
- Absolute neutrophil count (ANC) ≥ 1 x 10^9 /L
- Patients with bone marrow involvement or splenic sequestration: Platelet count ≥ 25 x 10^9 /L
- Patients with bone marrow involvement or splenic sequestration: Hg ≥ 7.0 g/dL
- Patients with bone marrow involvement or splenic sequestration: ANC ≥ 0.5 x 10^9 /L
- Negative serum pregnancy test within 2 days of initiating odronextamab for women of childbearing potential (WOCBP), defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year
- Fertile male and WOCBP patients must be willing to use highly effective contraceptive methods from study recruitment to at least 6 months after the CAR T-cell infusion
- Patients must not provide egg or sperm donation until at least 6 months after the completion of the last dose of Odron
Exclusion Criteria:
- Detectable cerebrospinal fluid malignant cells, or brain metastases, or with a history of cerebrospinal fluid malignant cells or brain metastases. Patients with a history of secondary central nervous system (CNS) lymphoma may be eligible provided that there has been no evidence of CNS disease from lymphoma for at least 3 months at the time of screening
- History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with central nervous system (CNS) involvement
- Standard anti-neoplastic chemotherapy (non-biologic) within 5-times the half-life or within 2 weeks, whichever is shorter, prior to first administration of study drug
- Standard radiotherapy within 2 weeks of first administration of study drug
- Prior treatment with an anti-CD20 x anti-CD3 bispecific therapy, unless all the following are met: disease responded to prior bispecific therapy (CR or PR per Lugano criteria) and did not experience disease progression within 12 months of the last dose of prior bispecific therapy, and the tumor must still express CD20 (CD20 examination per standard of care [SOC])
- Allogeneic stem cell transplantation
- Any CAR-T cell therapy
- Patients may not be receiving other investigational agents
- Treatment with rituximab, alemtuzumab, or other investigational or commercial biologic agent within 2 weeks prior to first administration of study drug
- Immunosuppressive therapy (other than biologic) within 2 weeks of first administration of study drug
- Treatment with an investigational non-biologic agent within 2 weeks of first administration of study drug
- History of allergic reactions attributed to compounds of similar chemical or biologic composition of study drug
- History of hypersensitivity to any compound in the tetracycline antibiotics group
- Concurrent active malignancy for which the patient is receiving systemic treatment, unless approved by PI
- Known active and uncontrolled bacterial, viral, fungal, mycobacterial, or other infection
- Evidence of significant concurrent disease or medical condition that could interfere with the conduct of the study, or put the patient at significant risk including, but not limited to, significant cardiovascular disease (e.g., New York Heart Association class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) and/or significant pulmonary disease (e.g., obstructive pulmonary disease and history of symptomatic bronchospasm)
- Ongoing systemic corticosteroid treatment, with the exception of corticosteroid use for other (non-tumor and non-immunosuppressive) indications up to a maximum of 10 mg/day of prednisone or equivalent. A short course of corticosteroid for lymphoma disease control during screening is allowed
- Infection with human immunodeficiency virus (unless viral load is undetectable and CD4 count ≥ 400) or chronic infection with hepatitis B virus or hepatitis C virus. Patients with hepatitis B (hepatitis B surface antigen positive [HepBsAg+]) with controlled infection were permitted upon consultation with the physician managing the infection
- Known hypersensitivity to both allopurinol and rasburicase
- Pregnant or breast-feeding women
- Administration of live vaccination within 28 days of first administration of study drug
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Treatment (odronextamab)
Patients receive odronextamab IV based on the following schedules:
Please see the Detailed Description for additional information. |
Undergo bone marrow biopsy
Andre navne:
Ancillary studies Undergo bone marrow aspiration Undergo lumbar puncture
Andre navne:
Undergo PET/CT
Andre navne:
Undergo PET/CT
Andre navne:
Undergo tissue biopsy
Andre navne:
Undergo leukapheresis
Andre navne:
Given IV
Andre navne:
Undergo collection of blood and oral or rectal swab samples
Andre navne:
Undergo CAR-T cell therapy
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Failure to undergo leukapheresis
Tidsramme: Up to 5 years
|
Will include failures due to disease progression or adverse events (AEs) due to odronextamab (Odron), or requirement of other lymphoma-directed therapy for bridging before leukapheresis due to lack of response. Will report the total number and percentage with 95% confidence interval (CI). |
Up to 5 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Receipt of chimeric antigen receptor T-cell therapy (CAR-T)
Tidsramme: Up to 5 years
|
Will estimate the total number and percentage with 95% CI of patients who receive CAR-T cell infusion. Patients who achieve complete response (CR) after 2 cycles of Odron and opt out of leukapheresis will be excluded from the estimation of the percentage. Will also report the reasons why patients do not eventually receive CAR-T. |
Up to 5 years
|
|
Overall response rate (ORR) following bridging prior to CAR-T infusion
Tidsramme: Up to 5 years
|
ORR includes CR, partial response, stable disease. Will report the total number and percentage with 95% CI of patients who achieve response on positron emission tomography/computed tomography (PET/CT) scans before CAR-T cell infusion. Patients who receive CAR-T cell infusion will be included in the estimation of this percentage. |
Up to 5 years
|
|
Progression free survival (PFS) following CAR-T infusion
Tidsramme: Up to 2 years
|
Will estimate the median with interquartile range of the progression free duration. Will also report the percentage with 95% CI. |
Up to 2 years
|
|
CR rate
Tidsramme: At 1 month after CAR-T
|
Will report the total number and percentage with 95% CI of patients who achieve CR on the PET/CT scans following CAR-T cell infusion. |
At 1 month after CAR-T
|
|
PFS in patients who achieve CR after 2 cycles of Odron, choose to opt out of CAR-T, and receive up to a total of 12 months of Odron
Tidsramme: Up to 5 years
|
Will report the median duration of PFS with 95% CI in this group of patients. |
Up to 5 years
|
|
Incidence of AEs
Tidsramme: Up to 90 days after the last dose of Odron or the initiation of the next lymphoma directed therapy, whichever occurs first
|
All AEs will be graded in severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Cytokine release syndrome and immune effector cell associated neurotoxicity syndrome will be graded by the American Society for Transplantation and Cellular Therapy Consensus Grading systems. Will report the rate and grade of each AE, including unsuccessful CAR-T production. |
Up to 90 days after the last dose of Odron or the initiation of the next lymphoma directed therapy, whichever occurs first
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Mengyang Di, MD, PhD, Fred Hutch/University of Washington Cancer Consortium
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Lymfesygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Lymfom, B-celle
- Lymfom
- Hemiske og lymfatiske sygdomme
- Lymfom, stor B-celle, diffus
- Undersøgelsesteknikker
- Terapeutik
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Punkteringer
- Kirurgiske procedurer, operative
- Cytologiske teknikker
- Cytodiagnose
- Diagnostiske teknikker, kirurgisk
- Kemiteknikker, analytisk
- Spektrumanalyse
- Biologisk terapi
- Cytaferese
- Fjernelse af blodkomponent
- Leukocytreduktionsprocedurer
- Celleseparation
- Diagnostiske teknikker, neurologisk
- Immunologiske teknikker
- Immunmodulering
- Adoptiv overførsel
- Immunisering, passiv
- Immunisering
- Immunoterapi
- Biopsi
- Håndtering af eksemplar
- Magnetisk resonansspektroskopi
- Leukapherese
- Spinal punktering
- Immunoterapi, adoptiv
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- RG1124641
- NCI-2024-10534 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- FHIRB0020747 (Anden identifikator: Fred Hutch/University of Washington Cancer Consortium)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .